The "Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com’s ...
UVA researcher Blandine Baffert, working in the lab of UVA Health’s Sanja Arandjelovic and collaborating with researchers in ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with systemic sclerosis will likely require multidisciplinary management with combination ...
Preclinical data showed promise in both systemic sclerosis bleomycin-induced mouse models and in patient-derived skin fibroblasts treated with EYD-001. The Food and Drug Administration (FDA) has ...
Scientists at the University of Virginia say they may be one step closer to stopping a rare and deadly disease that hardens ...
Please provide your email address to receive an email when new articles are posted on . Proton pump inhibitors with histamine 2 receptor antagonists reduced all-cause mortality in patients with ...
VIENNA — The use of immunosuppressive and antifibrotic drugs to treat skin and lung fibrosis leads updated recommendations from the European Alliance of Associations for Rheumatology (EULAR) for the ...
Systemic sclerosis causes the skin to tighten and harden resulting in a potentially fatal autoimmune condition that is associated with lung fibrosis and kidney disease. University of Michigan Health ...
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. Systemic sclerosis (SSc) or scleroderma is another rheumatic autoimmune disease that ...
LA JOLLA, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc. (MNOV), a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange (Code ...
Rituximab effectively reduced skin sclerosis and appeared to have a beneficial effect on interstitial lung disease (ILD) for patients with systemic sclerosis (SSc) in a randomized, clinical trial. At ...